Diovan

(valsartan)

ApprovedSmall molecule

Valsartan is used to treat high blood pressure and heart failure by helping blood vessels relax and allowing blood to flow more easily through the body.[2] Diovan is currently approved and in use across 42 indications[4].[1]

Diovan is one of 658 small molecule programs targeting Systolic Heart Failure. It is currently in Approved.

Indications

192

Total Trials

Active Trials

657

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Systolic Heart FailureActive, not recruiting

AtherosclerosisActive, not recruiting

Mitral RegurgitationActive, not recruiting

Myocardial FibrosisActive, not recruiting

Glucose IntoleranceActive, not recruiting

GlomerulonephritisActive, not recruiting

Ischemic StrokeActive, not recruiting

HypoxiaActive, not recruiting

Aortic Valve InsufficiencyApproved

Peripheral Arterial DiseaseApproved

Systolic Heart FailurePreclinical

Active, not recruiting

AtherosclerosisPreclinical

Active, not recruiting

Mitral RegurgitationApproved

Active, not recruiting

Myocardial FibrosisApproved

Active, not recruiting

Glucose IntoleranceApproved

Active, not recruiting

GlomerulonephritisApproved

Active, not recruiting

Ischemic StrokeApproved

Active, not recruiting

HypoxiaApproved

Active, not recruiting

Aortic Valve InsufficiencyApproved

Approved

Peripheral Arterial DiseaseApproved

Approved

Showing 10 of 42 indications

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Diovan

Novartis

Approved

17 2

Amidate

Pfizer

Preclinical

1 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Zemplar

Adriamycin

Savaysa

Xifaxan

2 9

Potassium Iodide

MMeda Pharmaceuticals

Preclinical

1 10

Oraverse

LLife Extension Foundation Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Obesity, Morbid

NCT03535376

Phase 2Recruiting

Kidney Disease

NCT05638880

Phase 3Not yet recruiting

Efficacy and Safety

NCT06771245

Phase 3Recruiting

Efficacy and Safety

NCT06643819

Q1 2027

Phase 2/3Recruiting

Study completion

NCT04971720

Q2 2027

Phase 2Recruiting

Diabetes Mellitus

NCT04055428

Clinical

Trials by Indication[1]

Hypertension29 trials

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

Completed· Takeda logo

Takeda·Phase 3·NCT02480764·612 enrolled

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension

Completed· Novartis logo

Novartis·Phase 4·NCT00809926·451 enrolled

Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With Hypertension

Completed·—·Phase 4·NCT02973035·104 enrolled

Show 26 more trials

A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg

Completed· Novartis logo

Novartis·Phase 3·NCT00241137·3,790 enrolled

Nighttime Valsartan in Hemodialysis Hypertension

Unknown status·FFifth Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT03594825·68 enrolled

Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy

Completed· Novartis logo

Novartis·Phase 4·NCT00351130·79 enrolled

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01281306·910 enrolled

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Completed· Novartis logo

Novartis·Phase 4·NCT00698646·384 enrolled

Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.

Completed· Novartis logo

Novartis·Phase 4·NCT01541189·200 enrolled

A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents

Enrolling by invitation·SShandong New Time Pharmaceutical Co., LTD·Phase 3·NCT06863987·342 enrolled

Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension

Completed· Novartis logo

Novartis·Phase 4·NCT00171054·125 enrolled

Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension

Completed·FFarma de Colombia SA·Phase 3·NCT01850160·124 enrolled

Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT00413413·1,134 enrolled

A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT00171028·90 enrolled

The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension

Completed·GGulhane School of Medicine·Phase 4·NCT00921570·105 enrolled

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

Completed· Novartis logo

Novartis·Phase 3·NCT00171041·265 enrolled

MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02177396·426 enrolled

Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Unknown status·LLanZhou University·N/A·NCT04800081·264 enrolled

Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise

Completed· Novartis logo

Novartis·Phase 2·NCT00819767·68 enrolled

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01681576·72 enrolled

Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02242318·440 enrolled

Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05545059·138 enrolled

A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT00457626·66 enrolled

Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy

Completed· Novartis logo

Novartis·Phase 4·NCT00304226·1,288 enrolled

VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis

Completed· Novartis logo

Novartis·Phase 3·NCT00171080·86 enrolled

Black Education and Treatment of Hypertension (BEAT HTN)

Completed·—·Phase 4·NCT00661895·99 enrolled

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT00446511·250 enrolled

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Completed· Novartis logo

Novartis·Phase 4·NCT00523549·229 enrolled

Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in Hypertension

Completed· Novartis logo

Novartis·Phase 4·NCT00333489·551 enrolled

Heart Failure17 trials

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Completed· Novartis logo

Novartis·Phase 3·NCT01920711·4,822 enrolled

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Completed· Novartis logo

Novartis·Phase 3·NCT02884206·592 enrolled

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure

Withdrawn·HHannover Medical School·Phase 2·NCT03415906

Show 14 more trials

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

Completed· Novartis logo

Novartis·Phase 4·NCT03300427·55 enrolled

Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

Completed· Novartis logo

Novartis·Phase 4·NCT00171106·150 enrolled

Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure

Unknown status·GGuangdong Provincial People's Hospital·N/A·NCT04458285·118 enrolled

A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure

Completed· Novartis logo

Novartis·Phase 2·NCT00294086·160 enrolled

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Completed·—·Phase 4·NCT05881720·80 enrolled

Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction

Unknown status·SSamsung Medical Center··NCT04803175·100 enrolled

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00391846·252 enrolled

The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure

Completed·AAmir Safwat·Phase 4·NCT04688294·60 enrolled

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Completed·—·Phase 4·NCT02816736·365 enrolled

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

Completed· Novartis logo

Novartis·Phase 2·NCT00887588·307 enrolled

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 2·NCT01353508·32 enrolled

The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure

Completed· Novartis logo

Novartis·Phase 4·NCT00241098·37 enrolled

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Completed· Novartis logo

Novartis·Phase 3·NCT02924727·5,669 enrolled

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)

Recruiting·VVirginia Commonwealth University·Preclinical·NCT05194111·70 enrolled

Essential Hypertension14 trials

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Completed· Takeda logo

Takeda·Phase 3·NCT00591578·984 enrolled

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Completed· Takeda logo

Takeda·Phase 3·NCT00696436·1,291 enrolled

A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)

Completed· Novartis logo

Novartis·Phase 3·NCT00311740·582 enrolled

Show 11 more trials

Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

Not yet recruiting·SSichuan Academy of Medical Sciences·Phase 4·NCT06501651·297 enrolled

A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia

Completed· Novartis logo

Novartis·Phase 3·NCT00254475·871 enrolled

Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT00699192·965 enrolled

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 2/3·NCT00425373·1,474 enrolled

Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT00437645·1,183 enrolled

Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT01001572·932 enrolled

A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 2·NCT01878201·75 enrolled

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT00549770·1,334 enrolled

A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT01672476·293 enrolled

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Completed·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 3·NCT05359068·957 enrolled

A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Efficacy and Safety of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

Completed·WWuhan Createrna Science and Technology Co., Ltd·Phase 2·NCT07700875·391 enrolled

ALS7 trials

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

Completed·CCarelon Research·Phase 2·NCT01912534·211 enrolled

Chronopharmacology of Valsartan in Normotensive Subjects

Completed·—·Phase 1·NCT02631031·24 enrolled

Bioequivalence Study of Valsartan 320mg Tablets Under Fed Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT02197494·40 enrolled

Show 4 more trials

To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone

Completed· Novartis logo

Novartis·Phase 4·NCT01070043·60 enrolled

The DDI Study of SP2086 and Valsartan

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02817217·24 enrolled

Antiproteinuric Effect of Valsartan and Lisinopril

Completed· Novartis logo

Novartis·Phase 4·NCT00171574·124 enrolled

To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 1·NCT00415883·40 enrolled

Interaction6 trials

Physiologic Interactions Between the Adrenal- and the Parathyroid Glands

Completed·UUniversity of Aarhus·Phase 4·NCT02572960·81 enrolled

The Drug-drug Interaction of SP2086 and Valsartan

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02815657·16 enrolled

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)

Completed·—·N/A·NCT01767298·24 enrolled

Show 3 more trials

Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802

Completed·LLG Chem·Phase 1·NCT03532854·42 enrolled

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide

Completed·—·N/A·NCT01767259·24 enrolled

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Completed·CChipscreen Biosciences, Ltd.·Phase 1·NCT05681273·48 enrolled

82 more indications

Blood Pressure5 trials

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering

Completed·NNara Medical University·Phase 4·NCT01609959·70 enrolled

Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day

Completed· Novartis logo

Novartis·Phase 4·NCT00700271·478 enrolled

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

Active, not recruiting·OOhio State University·Phase 4·NCT03938389·90 enrolled

Show 2 more trials

The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT00185055·20 enrolled

Valsartan Intensified Primary Care Reduction of Blood Pressure Study

Completed· Novartis logo

Novartis·Phase 4·NCT00902304·2,337 enrolled

Diabetes Mellitus4 trials

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

Completed· Novartis logo

Novartis·Phase 4·NCT00927394·1,143 enrolled

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

Completed· Novartis logo

Novartis·Phase 4·NCT00241085·392 enrolled

A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril

Terminated· Novartis logo

Novartis·Phase 4·NCT00171119·81 enrolled

Show 1 more trial

The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals (NAUTICAL)

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT04055428·200 enrolled

Metabolic Syndrome4 trials

Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome

Completed· Novartis logo

Novartis·Phase 4·NCT00241150·80 enrolled

Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome

Completed· Novartis logo

Novartis·Phase 3·NCT00394745·45 enrolled

Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)

Unknown status·—·Phase 4·NCT00790946·250 enrolled

Show 1 more trial

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

Completed· Novartis logo

Novartis·Phase 4·NCT00821574·144 enrolled

High Blood Pressure4 trials

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

Completed· Novartis logo

Novartis·Phase 4·NCT00170924·317 enrolled

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

Completed· Novartis logo

Novartis·Phase 3·NCT00433836·300 enrolled

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Completed· Novartis logo

Novartis·Phase 3·NCT00386607·601 enrolled

Show 1 more trial

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

Completed· Novartis logo

Novartis·Phase 4·NCT00171353·109 enrolled

Hypertensive4 trials

Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women

Unknown status·LLanZhou University·N/A·NCT03432468·102 enrolled

Role of ARNi in Ventricular Remodeling in Hypertensive LVH

Completed·NNational Heart Centre Singapore·Phase 2·NCT03553810·80 enrolled

A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy

Completed· Novartis logo

Novartis·Phase 3·NCT00327145·894 enrolled

Show 1 more trial

Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD

Withdrawn·UUniversity of Maryland, Baltimore·Phase 4·NCT03279861

Kidney Disease3 trials

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Terminated·—·Phase 4·NCT01129557·46 enrolled

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

Recruiting·MMostafa Bahaa·Phase 2·NCT05638880·60 enrolled

Optimal Treatment for Kidney Disease in HIV Infected Adults

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00089518

Atrial Fibrillation3 trials

The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)

Terminated·IIntermountain Health Care, Inc.·Phase 4·NCT00343499·200 enrolled

Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT05528419·320 enrolled

GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

Completed·GGruppo di Ricerca GISSI·Phase 3·NCT00376272·1,442 enrolled

Efficacy and Safety3 trials

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

Completed·TTrinity Hypertension & Metabolic Research Institute·Phase 4·NCT03180593·30 enrolled

A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT06771245·606 enrolled

Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

Recruiting· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 3·NCT06643819·324 enrolled

Left Ventricular Hypertrophy3 trials

Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

Completed·MMustafa Kemal University·Phase 4·NCT01425411·38 enrolled

Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy

Completed· Novartis logo

Novartis·Phase 3·NCT00446563·90 enrolled

Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)

Terminated·FFundación Lindavista del Corazón AC·Phase 3·NCT00738972·12 enrolled

Type 2 Diabetes3 trials

Preventing ESRD in Overt Nephropathy of Type 2 Diabetes

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT00494715·102 enrolled

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

Completed·UUniversity of Copenhagen·Phase 4·NCT03893526·12 enrolled

Preventing Microalbuminuria in Type 2 Diabetes

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT00503152·612 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00396656·30 enrolled

Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00409643·1,259 enrolled

Stroke2 trials

Blood Pressure Lowering in Acute Stroke Trial

Withdrawn·SStanford University·Phase 4·NCT01400256

Blood Pressure Lowering in Acute Stroke Trial (BLAST)

Withdrawn·SStanford University·N/A·NCT00627991

Cardiovascular Disease2 trials

Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

Terminated·KKumamoto University·Phase 4·NCT00140790·1,000 enrolled

Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease

Completed·KKVT-Study Group·Phase 4·NCT00190580·312 enrolled

Type 2 Diabetes Mellitus2 trials

Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus

Completed·—·Phase 4·NCT00982358·121 enrolled

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Completed· Novartis logo

Novartis·Phase 4·NCT00550095·509 enrolled

IgA Nephropathy2 trials

A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy

Completed·GGuangdong Provincial People's Hospital·Phase 4·NCT00426348·75 enrolled

Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT02765594·98 enrolled

Tics2 trials

A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers

Completed· Astellas logo

Astellas·Phase 1·NCT01115972·24 enrolled

Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?

Unknown status·—·N/A·NCT00732966·30 enrolled

Albuminuria2 trials

Rationale and Design for Shiga Microalbuminuria Reduction Trial

Unknown status·SShiga University·Phase 4·NCT00202618·160 enrolled

VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria

Completed· Novartis logo

Novartis·Phase 3·NCT00171067·134 enrolled

Chronic Kidney Disease2 trials

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Terminated· AstraZeneca logo

AstraZeneca·Phase 3·NCT05056727·1,112 enrolled

Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease

Unknown status·—·Phase 4·NCT02299310·60 enrolled

Diabetes2 trials

Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes

Completed· Novartis logo

Novartis·Phase 4·NCT00241124·1,099 enrolled

Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes

Completed·KKorea University Anam Hospital·Phase 4·NCT00599885·72 enrolled

Mortality2 trials

A Morbidity-Mortality and Remodeling Study With Valsartan

Unknown status·JJikei University School of Medicine·Phase 4·NCT00133328·3,000 enrolled

Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)

Completed·KKyoto Prefectural University of Medicine·Phase 4·NCT00149227·3,031 enrolled

Nephropathy2 trials

Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

Unknown status·GGuangdong Provincial People's Hospital·N/A·NCT00655330·170 enrolled

1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00153023·885 enrolled

Glucose intolerance1 trial

Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance

Completed·NNagoya University·Phase 4·NCT00129233·1,150 enrolled

ESS1 trial

FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)

Completed· Bayer logo

Bayer·Phase 4·NCT01071122·365 enrolled

Carvedilol1 trial

Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

Completed·SState University of New York at Buffalo·Phase 3·NCT00657241·30 enrolled

Oxidative Stress1 trial

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

Completed·VVanderbilt University·Phase 2·NCT00732069·19 enrolled

Overweight1 trial

VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women

Completed· Novartis logo

Novartis·Phase 4·NCT00171132·64 enrolled

Angina Pectoris1 trial

Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris

Terminated·UUniversity of Aarhus·N/A·NCT00424801·10 enrolled

Oxygen Consumption1 trial

24 Hour Ambulatory Cardiac Oxygen Consumption

Completed·SState University of New York at Buffalo·Phase 3·NCT05170061·26 enrolled

Plaque1 trial

Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent

Completed·SSeung-Jung Park·Phase 4·NCT00589732·220 enrolled

Prospective1 trial

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

Unknown status·MMark Ledwidge·Phase 2·NCT04687111·250 enrolled

Dapagliflozin1 trial

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00839683·24 enrolled

Acute Respiratory Distress Syndrome1 trial

Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease

Terminated·RRadboud University Medical Center·Phase 4·NCT04335786·23 enrolled

Exercise1 trial

Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II

Unknown status·TThe University of Hong Kong·Phase 4·NCT05269615·80 enrolled

Home Blood Pressure1 trial

Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study

Completed·KKitakyushu-Tsuyazaki Hospital·Phase 4·NCT00460213·103 enrolled

Glomerulonephritis1 trial

Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

Recruiting·TThe First Affiliated Hospital of Dalian Medical University·Phase 4·NCT04263922·466 enrolled

Vasoconstriction1 trial

Effect of DPP4 Inhibition on Vasoconstriction

Completed·VVanderbilt University·Phase 4·NCT02639637·18 enrolled

Hyperlipidemia1 trial

Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

Completed·LLG Life Sciences·Phase 3·NCT01918332·168 enrolled

Acute Coronary Syndrome1 trial

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Completed· Novartis logo

Novartis·Phase 2·NCT00409578·1,101 enrolled

Pulmonary Hypertension1 trial

Repurposing Valsartan May Protect Against Pulmonary Hypertension

Recruiting·UUniversity of Washington·Phase 2·NCT06053580·60 enrolled

Endothelial Dysfunction1 trial

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

Terminated·VVanderbilt University·Phase 3·NCT00878969·78 enrolled

Renal Transplant1 trial

Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine

Unknown status·JJosep m Cruzado·Phase 4·NCT04769778·180 enrolled

Single Dose1 trial

Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT00310778·64 enrolled

Metabolism1 trial

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Suspended·UUniversity of Pennsylvania·Phase 3·NCT03508739·25 enrolled

Pediatric Patients1 trial

Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients

Completed· Novartis logo

Novartis·Phase 1·NCT01447485·12 enrolled

T2DM1 trial

Effect of HMP on Diabetic Microangiopaemia in T2DM

Completed·—·Phase 4·NCT05095922·40 enrolled

Metformin1 trial

A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04859452·56 enrolled

Cytokines1 trial

Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level

Completed·—·Phase 4·NCT03990480·230 enrolled

Double-blind1 trial

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Completed· Novartis logo

Novartis·Phase 3·NCT03066804·2,572 enrolled

Drug1 trial

Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.

Completed· Novartis logo

Novartis·Phase 1·NCT00416728·32 enrolled

HFpEF1 trial

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Completed· Novartis logo

Novartis·Phase 3·NCT03988634·467 enrolled

Unknown status·—·Phase 4·NCT02403349·105 enrolled

ART1 trial

A Study of LY900020 in Healthy Chinese Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT04047940·32 enrolled

Hypertrophy1 trial

LCZ696 in Advanced LV Hypertrophy and HFpEF

Completed·NNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation·Phase 2·NCT03928158·61 enrolled

Empagliflozin1 trial

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT07331389·111 enrolled

Peritoneal Dialysis1 trial

Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients

Completed·SSun Yat-sen University·N/A·NCT00721773·200 enrolled

Mitral regurgitation1 trial

Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation

Completed·—·Phase 4·NCT02687932·118 enrolled

Carotid Artery Disease1 trial

Effect of Valsartan on Carotid Artery Disease

Completed·EEmory University·Phase 2·NCT00208767·120 enrolled

Catheter Ablation1 trial

Effect of ARNI in Patients With Persistent AF and Enlarged Left Atrium After Catheter Ablation

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT03791723·90 enrolled

Oral1 trial

Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums

Completed·UUniversity Medicine Greifswald·Phase 1·NCT03012763·9 enrolled

ARB1 trial

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Terminated·VVanderbilt University Medical Center·Phase 4·NCT03738878·4 enrolled

Mitochondria1 trial

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

Terminated·WWake Forest University Health Sciences·N/A·NCT02606279·1 enrolled

HIE1 trial

Fimasartan Achieving SBP Target (FAST) Study

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 4·NCT02495324·369 enrolled

Proteinuria1 trial

The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria

Unknown status·SSamsung Medical Center·Phase 4·NCT00858299·500 enrolled

Hypoxia1 trial

Intermittent Hypoxia 2: Cardiovascular and Metabolism

Terminated·UUniversity Hospital, Grenoble·Phase 4·NCT02058823·12 enrolled

Medication1 trial

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

Completed· Novartis logo

Novartis·Phase 1·NCT00416468·32 enrolled

Impaired glucose tolerance1 trial

Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance

Completed· Novartis logo

Novartis·Phase 4·NCT00241072·27 enrolled

Aortic Stenosis1 trial

Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study

Withdrawn·UUniversity Hospital, Limoges·Phase 2/3·NCT03315832

Systolic Dysfunction1 trial

The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI

Completed·NNHS Greater Glasgow and Clyde·Phase 3·NCT03552575·93 enrolled

Myocardial Infarction1 trial

The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

Not yet recruiting·WWest China Hospital·Phase 3·NCT04912167·376 enrolled

COVID-191 trial

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated·UUniversity of British Columbia·Phase 3·NCT04606563·341 enrolled

Cardiotoxicity1 trial

Prevention of CHOP-induced Chronic Cardiotoxicity

Completed·OOsaka City University·Phase 4·NCT00162955·150 enrolled

Dilated Cardiomyopathy1 trial

Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy

Completed·XXijing Hospital·Phase 4·NCT01917149·480 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT02197442·36 enrolled

Children1 trial

Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age

Completed· Novartis logo

Novartis·Phase 3·NCT01365481·150 enrolled

Takotsubo cardiomyopathy1 trial

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Recruiting·UUniversity of Edinburgh·Preclinical·NCT07491718·100 enrolled

Heart Failure With Preserved Ejection Fraction1 trial

Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction

Withdrawn·BBrigham and Women's Hospital·Approved·NCT06536309

Atrial Functional Mitral Regurgitation1 trial

Effects of VALsartan On atRIAl Mitral Regurgitation: A Pilot Randomized Controlled Trial

Recruiting·JJonathan Beaudoin·Preclinical·NCT07539298·50 enrolled

Obesity, Morbid1 trial

Bariatric Surgery and Pharmacokinetics of Valsartan: BAR-MEDS Valsartan

Recruiting·NNorwegian University of Science and Technology··NCT03535376·12 enrolled

Type 2 Diabetes (T2DM)1 trial

A Double-Blind, Randomized, Active-Controlled Phase 2a Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TriGlytza®-01 in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy

Not yet recruiting·MMyopharm Limited·Phase 2·NCT07139405·48 enrolled

Unspecified1 trial

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

Recruiting·UUniversity of Alabama at Birmingham·Phase 2/3·NCT04971720·160 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 23, 1996

DIOVAN

NDA NDA020665

Mar 6, 1998

DIOVAN HCT

NDA NDA020818

Feb 18, 1999

DIOVAN HCT

NDA NDA020818

Apr 28, 1999

DIOVAN HCT

NDA NDA020818

Jun 16, 1999

DIOVAN HCT

NDA NDA020818

Mar 1, 2000

DIOVAN HCT

NDA NDA020818

Apr 18, 2000

DIOVAN HCT

NDA NDA020818

May 10, 2000

DIOVAN HCT

NDA NDA020818

Nov 2, 2000

DIOVAN HCT

NDA NDA020818

Sep 27, 2001

DIOVAN HCT

NDA NDA020818

Oct 23, 2001

DIOVAN HCT

NDA NDA020818

Jan 17, 2002

DIOVAN HCT

NDA NDA020818

Apr 5, 2002

DIOVAN

NDA NDA021283

Apr 29, 2002

DIOVAN

NDA NDA021283

Apr 29, 2002

DIOVAN HCT

NDA NDA020818

Aug 1, 2002

DIOVAN HCT

NDA NDA020818

Aug 1, 2002

DIOVAN

NDA NDA021283

Aug 14, 2002

DIOVAN

NDA NDA021283

Aug 14, 2002

DIOVAN

NDA NDA021283

Sep 13, 2002

DIOVAN

NDA NDA021283

Nov 6, 2002

DIOVAN

NDA NDA021283

Nov 6, 2002

DIOVAN HCT

NDA NDA020818

Jan 15, 2003

DIOVAN HCT

NDA NDA020818

Nov 30, 2004

DIOVAN

NDA NDA021283

Jul 7, 2005

DIOVAN HCT

NDA NDA020818

Aug 3, 2005

DIOVAN

NDA NDA021283

Apr 28, 2006

DIOVAN HCT

NDA NDA020818

Nov 20, 2006

DIOVAN HCT

NDA NDA020818

Nov 22, 2006

DIOVAN

NDA NDA021283

Aug 17, 2007

DIOVAN

NDA NDA021283

Sep 6, 2007

DIOVAN HCT

NDA NDA020818

Nov 29, 2007

DIOVAN

NDA NDA021283

Jul 31, 2008

DIOVAN HCT

NDA NDA020818

Jun 15, 2009

DIOVAN

NDA NDA021283

Apr 21, 2010

DIOVAN HCT

NDA NDA020818

Jun 3, 2011

DIOVAN

NDA NDA021283

Jun 3, 2011

DIOVAN HCT

NDA NDA020818

Dec 12, 2011

DIOVAN

NDA NDA021283

Dec 12, 2011

DIOVAN HCT

NDA NDA020818

Dec 12, 2011

DIOVAN HCT

NDA NDA020818

Jan 18, 2012

DIOVAN HCT

NDA NDA020818

Jan 18, 2012

DIOVAN

NDA NDA021283

Feb 16, 2012

DIOVAN HCT

NDA NDA020818

Feb 28, 2012

DIOVAN

NDA NDA021283

Jul 26, 2012

DIOVAN HCT

NDA NDA020818

Jul 26, 2012

DIOVAN

NDA NDA021283

Oct 4, 2012

DIOVAN HCT

NDA NDA020818

Oct 4, 2012

DIOVAN

NDA NDA021283

Oct 18, 2013

DIOVAN

NDA NDA021283

Mar 17, 2014

DIOVAN

NDA NDA021283

Mar 17, 2014

DIOVAN

NDA NDA021283

Mar 17, 2014

DIOVAN HCT

NDA NDA020818

Mar 17, 2014

DIOVAN HCT

NDA NDA020818

Apr 23, 2014

DIOVAN HCT

NDA NDA020818

May 30, 2014

DIOVAN HCT

NDA NDA020818

Sep 24, 2014

DIOVAN HCT

NDA NDA020818

Sep 26, 2014

DIOVAN

NDA NDA021283

May 22, 2015

DIOVAN HCT

NDA NDA020818

Jul 27, 2015

DIOVAN

NDA NDA021283

Jul 27, 2015

DIOVAN HCT

NDA NDA020818

Jul 31, 2015

DIOVAN

NDA NDA021283

Nov 13, 2015

DIOVAN HCT

NDA NDA020818

Aug 1, 2016

DIOVAN HCT

NDA NDA020818

Feb 3, 2017

DIOVAN

NDA NDA021283

Dec 19, 2017

PREXXARTAN

NDA NDA209139

Jun 12, 2019

DIOVAN

NDA NDA021283

Jun 12, 2019

DIOVAN HCT

NDA NDA020818

Aug 20, 2020

DIOVAN HCT

NDA NDA020818

Apr 19, 2021

DIOVAN

NDA NDA021283

Jul 22, 2021

DIOVAN

NDA NDA021283

Jul 21, 2025

DIOVAN

NDA NDA021283

Sources

References

[1]
ClinicalTrials.gov — 192 trial records for valsartan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Diovan drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — valsartan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for valsartan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021283). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Type-1 Angiotensin II Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Diovan

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Hypertension29 trials

Heart Failure17 trials

Essential Hypertension14 trials

ALS7 trials

Interaction6 trials

Blood Pressure5 trials

Diabetes Mellitus4 trials

Metabolic Syndrome4 trials

High Blood Pressure4 trials

Hypertensive4 trials

Kidney Disease3 trials

Atrial Fibrillation3 trials

Efficacy and Safety3 trials

Left Ventricular Hypertrophy3 trials

Type 2 Diabetes3 trials

Safety and Efficacy2 trials

Stroke2 trials

Cardiovascular Disease2 trials

Type 2 Diabetes Mellitus2 trials

IgA Nephropathy2 trials

Tics2 trials

Albuminuria2 trials

Chronic Kidney Disease2 trials

Diabetes2 trials

Mortality2 trials

Nephropathy2 trials

Glucose intolerance1 trial

ESS1 trial

Carvedilol1 trial

Oxidative Stress1 trial

Overweight1 trial

Angina Pectoris1 trial

Oxygen Consumption1 trial

Plaque1 trial

Prospective1 trial

Dapagliflozin1 trial

Acute Respiratory Distress Syndrome1 trial

Exercise1 trial

Home Blood Pressure1 trial

Glomerulonephritis1 trial

Vasoconstriction1 trial

Hyperlipidemia1 trial

Acute Coronary Syndrome1 trial

Pulmonary Hypertension1 trial

Endothelial Dysfunction1 trial

Renal Transplant1 trial

Single Dose1 trial

Metabolism1 trial

Pediatric Patients1 trial

T2DM1 trial

Metformin1 trial

Cytokines1 trial

Double-blind1 trial

Drug1 trial

HFpEF1 trial

Regression1 trial

Treatment1 trial

Ischemic stroke1 trial

ART1 trial

Hypertrophy1 trial

Empagliflozin1 trial

Peritoneal Dialysis1 trial

Mitral regurgitation1 trial

Carotid Artery Disease1 trial

Catheter Ablation1 trial

Oral1 trial

ARB1 trial

Mitochondria1 trial

HIE1 trial

Proteinuria1 trial

Hypoxia1 trial

Medication1 trial